Get Flat 20% Discount on All Medications
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      MDRNA gets FDA approval for Osteoporosis Nasal Spray


      MDRNA Inc. said the U.S. Food and Drug Administration (FDA) has approved its application for a nasal spray for treating Osteoporosis and that the product will be sold by the Bothell biotech’s partner, Par Pharmaceutical Companies Inc.

      Shares in MDRNA (NASDAQ: MRNA) soared in Tuesday trading, rising more than 75 percent, rising $1.16 to close at $2.70.

      MDRNA originally developed the calcitonin-salmon nasal spray when the company was known as Nastech Pharmaceutical Co. in the early 2000s and the company signed a deal with Par five years ago to market and sell the product.

      “Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs,” said J. Michael French, president and CEO of MDRNA, in a statement.

      June 10, 2009


      Share this Article!

    Back to top^